Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea Pharmaceutica (SIX: BSLN) reports its first ($5m) milestone payment for 2026
Published by Jyoti Prakash, CFA

Basilea Pharmaceutica has reported its first milestone payment for FY26, receiving $5m from Pfizer following Cresemba’s sales in Asia Pacific and China surpassing a predefined contractual threshold. The milestone compares favourably with the $2.5m payments received in March and June 2025, suggesting that a materially higher sales tier has now been achieved. We view this as evidence of continued commercial momentum, particularly in China, which management estimates to be c 20% of Cresemba’s total addressable opportunity.

Global in-market sales of Cresemba reached c $693m for the twelve months ended September 2025, implying c 27% y-o-y growth and reinforcing its position as the leading branded antifungal globally. On the back of the stronger-than-expected sales trajectory, we recently upgraded our peak sales estimate to c $900m in our latest research update.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.